# Elevated Serum MCP‐2 and TARC Associated With Increased Risk of Death in Guamanian ALS Patients

**Authors:** Risana N. Chowdhury, Mus'ab A. Azam, Suhaib A. Azam, Shteynman Lana, Erin N. Culver, Ralph M. Garruto, Katherine Wander

PMC · DOI: 10.1111/ene.70088 · 2025-02-25

## TL;DR

High levels of two immune proteins in Guamanian ALS patients are linked to shorter survival times, suggesting a role in disease progression.

## Contribution

Identifies MCP-2 and TARC as novel serum biomarkers associated with increased mortality risk in Guamanian ALS patients.

## Key findings

- Elevated MCP-2 and TARC levels correlate with a 38% higher risk of death in Guamanian ALS patients.
- Factor analysis revealed two key cytokine patterns explaining 68% of the variation in immune markers.
- Inflammation is linked to shorter lifespan in this unique ALS population.

## Abstract

This study explores the relationship between inflammation and longevity in a high‐incidence focus of amyotrophic lateral sclerosis (ALS) in post‐WWII Guam. Characteristics of this focus include the sudden appearance of the disease in high numbers and the unusually long lifespan (without medical interventions) seen in some cases. We used bio‐banked specimens to evaluate the relationship between serum immunoregulators and survival time.

We evaluated sera from 69 Guam ALS cases collected within 2 years of symptom onset by NIH researchers from 1950 to 1983 for 11 immunoregulators via ELISA (CRP, eotaxin‐1, RANTES, IL‐6, IL‐8, IL‐10, IFN‐γ, IP‐10, MCP‐1, MCP‐2 and TARC). Factor analysis identified two factors responsible for ~68% of the variation in the data. We estimated Cox proportional hazards models to identify immunoregulators associated with time to death.

Each 10‐unit increase in factor 2 cytokines (MCP‐2 and TARC) was associated with a 38% increase in the risk of death (HR: 1.38; 95% CI: 1.19, 1.65; p: 0.00). Discussion: Like sporadic ALS cases worldwide, inflammation is associated with a shortened lifespan in Guamanian ALS; more specifically, our findings suggest serum levels of MCP‐2 and TARC at onset may predict disease duration. Further investigation is needed to determine the role of these immunoregulators in disease prognosis and as targets for diagnostic and therapeutic interventions.

## Linked entities

- **Proteins:** CCL8 (C-C motif chemokine ligand 8), CCL17 (C-C motif chemokine ligand 17), CRP (C-reactive protein), CCL5 (C-C motif chemokine ligand 5), IL6 (interleukin 6), CXCL8 (C-X-C motif chemokine ligand 8), IL10 (interleukin 10), IFNG (interferon gamma), CXCL10 (C-X-C motif chemokine ligand 10), CCL2 (C-C motif chemokine ligand 2)
- **Diseases:** amyotrophic lateral sclerosis (MONDO:0004976), ALS (MONDO:0004976)

## Full-text entities

- **Genes:** IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, CCL8 (C-C motif chemokine ligand 8) [NCBI Gene 6355] {aka HC14, MCP-2, MCP2, SCYA10, SCYA8}, CCL17 (C-C motif chemokine ligand 17) [NCBI Gene 6361] {aka A-152E5.3, ABCD-2, SCYA17, TARC}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, CCL11 (C-C motif chemokine ligand 11) [NCBI Gene 6356] {aka SCYA11}
- **Diseases:** ALS (MESH:D000690), Death (MESH:D003643), inflammation (MESH:D007249)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11851731/full.md

---
Source: https://tomesphere.com/paper/PMC11851731